Gene-expression microarrays provide new prognostic and predictive tests for breast cancer.

Abstract:

:Wide availability of systemic therapy agents has led to a considerable decline in mortality from breast cancer. However, the biology of breast cancer remains poorly understood. Currently, highly accurate markers to predict prognosis and probability of response to a given systemic therapy on an individual basis are lacking, and routinely used clinicopathologic variables fail to fully capture the heterogeneity of breast cancer. As a result, many patients are overtreated, whereas others may not receive the necessary therapy. It has been hypothesized that molecular differences in breast cancers might account for the heterogeneous potential in growth, invasion and metastasis in each individual tumor. Gene-expression microarrays have been extensively applied in breast cancer research in the hope that a combination of multiple genes (i.e., gene signatures) will more informatively predict disease outcome and response to a specific systemic therapy. This technique holds substantial promise for optimizing clinical decision making and tailoring therapeutic regimens to individual patients in the near future. This review focuses on the recent progression in feasibility and reliability of gene-expression microarrays in identifying new prognostic and predictive indicators of breast cancer.

journal_name

Pharmacogenomics

journal_title

Pharmacogenomics

authors

Gong Y,Symmans WF,Pusztai L

doi

10.2217/14622416.8.10.1359

subject

Has Abstract

pub_date

2007-10-01 00:00:00

pages

1359-68

issue

10

eissn

1462-2416

issn

1744-8042

journal_volume

8

pub_type

杂志文章,评审
  • Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.

    abstract::The extent of genetic variation found in drug metabolism genes and its contribution to interindividual variation in response to medication remains incompletely understood. To better determine the identity and frequency of variation in 11 phase I drug metabolism genes, the exons and flanking intronic regions of the cyt...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.1517/14622416.5.7.895

    authors: Solus JF,Arietta BJ,Harris JR,Sexton DP,Steward JQ,McMunn C,Ihrie P,Mehall JM,Edwards TL,Dawson EP

    更新日期:2004-10-01 00:00:00

  • Gene expression profile analysis: an emerging approach to investigate mechanisms of genotoxicity.

    abstract::The response to stress triggers transcriptional activation of genes involved in cell survival and/or cell death. Thus, the monitoring of gene expression levels in large gene sets or whole genomes in response to various agents (toxicogenomics) has been proposed as a tool for investigating mechanisms of toxicity. Althou...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.6.4.419

    authors: Aubrecht J,Caba E

    更新日期:2005-06-01 00:00:00

  • Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy.

    abstract:UNLABELLED:Glutathione S-transferases (GSTs) participate in the detoxification of chemotherapeutic agents. Genetic polymorphisms in GST genes (GSTP1 Ile105Val, copy-number variants of GSTM1 and GSTT1) that lead to diminished enzyme activity have been associated with increased chemotherapeutic treatment benefit in color...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.09.132

    authors: Funke S,Timofeeva M,Risch A,Hoffmeister M,Stegmaier C,Seiler CM,Brenner H,Chang-Claude J

    更新日期:2010-01-01 00:00:00

  • ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations.

    abstract::COVID-19 utilizes the ACE2 pathway as a means of infection. Early data on COVID-19 suggest heterogeneity in the severity of symptoms during transmission and infection ranging from no symptoms to death. The source of this heterogeneity is likely multifaceted and may have a genetic component. Demographic and clinical co...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2020-0048

    authors: Snyder EM,Johnson BD

    更新日期:2020-07-01 00:00:00

  • Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients.

    abstract::This review will summarize the role of pharmacogenetics in the natural history of hepatitis C, particularly in patients with HIV/HCV and will take the perspective of pharmacogenetics and its influence on the response to antiviral therapy and the susceptibility to develop adverse effects. This review will also devote a...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2018-0046

    authors: Frias M,Rivero-Juárez A,López-López P,Rivero A

    更新日期:2018-08-01 00:00:00

  • Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms.

    abstract:AIM:We investigated 16 polymorphisms from three genes, dopamine receptor D2 (DRD2), catechol-O-methyl transferase (COMT) and brain derived neurotrophic factor (BDNF), which are involved in the dopaminergic pathways, and have been reported to be associated with susceptibility to schizophrenia and response to antipsychot...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.10.2.277

    authors: Gupta M,Chauhan C,Bhatnagar P,Gupta S,Grover S,Singh PK,Purushottam M,Mukherjee O,Jain S,Brahmachari SK,Kukreti R

    更新日期:2009-02-01 00:00:00

  • Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.

    abstract:AIM:We conducted a genome-wide association study using the Illumina Exome Array to identify coding SNPs that may explain additional warfarin dose variability. PATIENTS & METHODS:Analysis was performed after adjustment for clinical variables and genetic factors known to influence warfarin dose among 1680 warfarin users...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2017-0046

    authors: Liu N,Irvin MR,Zhi D,Patki A,Beasley TM,Nickerson DA,Hill CE,Chen J,Kimmel SE,Limdi NA

    更新日期:2017-07-01 00:00:00

  • miRNAs: from neurogeneration to neurodegeneration.

    abstract::miRNAs are reported to sequence-specifically control the translation of target mRNAs by binding to 3 UTRs. The abundant expression of miRNAs in the brain highlights their biological significance in neurodevelopment. Many studies have shown that miRNAs are involved in a variety of functions, including developmental tra...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.8.971

    authors: Singh SK

    更新日期:2007-08-01 00:00:00

  • The impact of HER2 overexpression on the miRNA and circRNA transcriptomes in two breast cell lines and their vesicles.

    abstract::HER2 upregulation is related with poor outcome in many tumor types. Whereas anti-HER2 treatment is the standard approach as adjuvant therapy in HER2-overexpressing breast cancer, the frequent relapses reinforce the need for alternative treatments. Here we used next-generation sequencing (NGS) to evaluate miRNAs and ci...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs-2018-0182

    authors: Galli de Amorim M,Branco G,Valieris R,Tarcitano E,Tojal da Silva I,Ferreira de Araújo L,Noronha Nunes D,Dias-Neto E

    更新日期:2019-05-01 00:00:00

  • Genomics-based drug design targets the AT-rich malaria parasite: implications for antiparasite chemotherapy.

    abstract::Evaluation of: Woynarowski JM, Krugliak M, Ginsburg H: Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs. Mol. Biochem. Parasitol. 154(1), 70-81 (2007) [1] . The sequencing of the malaria genome sought to expose the parasite's ability to cause disease and ident...

    journal_title:Pharmacogenomics

    pub_type: 评论,杂志文章

    doi:10.2217/14622416.8.9.1267

    authors: Yanow SK,Purcell LA,Lee M,Spithill TW

    更新日期:2007-09-01 00:00:00

  • MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine.

    abstract::Referred to as the micromanagers of gene expression, microRNAs (miRNAs) are evolutionarily conserved small noncoding RNAs. Polymorphisms in the miRNA pathway (miR-polymorphisms) are emerging as powerful tools to study the biology of a disease and have the potential to be used in disease prognosis and diagnosis. Detect...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.10.3.399

    authors: Mishra PJ,Bertino JR

    更新日期:2009-03-01 00:00:00

  • Stem cell-derived neurons in the development of targeted treatment for schizophrenia and bipolar disorder.

    abstract::The recent advent of induced pluripotent stem cells has enabled the study of patient-specific and disease-related neurons in vitro and has facilitated new directions of inquiry into disease mechanisms. With these approaches, we now have the possibility of correlating ex vivo cellular phenotypes with individual patient...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2016-0187

    authors: Watmuff B,Liu B,Karmacharya R

    更新日期:2017-04-01 00:00:00

  • microRNA expression changes after atrial fibrillation catheter ablation.

    abstract::Atrial fibrillation (AF) is most common arrhythmia in general population, with increasing trend in mortality and morbidity. Electrophysiological and structural abnormalities, promoting abnormal impulse formation and propagation, lead to this disease. AF catheter ablation is related to a not small percentage of nonresp...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.15.117

    authors: Sardu C,Santamaria M,Paolisso G,Marfella R

    更新日期:2015-11-01 00:00:00

  • Genetic factors that confer sensitivity to HAART in HIV-infected subjects: implication of a benefit of an earlier initiation of HAART.

    abstract::EVALUATION OF: Ahuja SK, Kulkarni H, Catano G et al.: CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat. Med. 14(4), 413-420 (2008). It is widely accepted that the effect of highly active antiretroviral therapy (HAART) varies widely among HIV...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.9.1347

    authors: Nakajima T,Kimura A

    更新日期:2008-09-01 00:00:00

  • Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain.

    abstract:AIM:GLP-1 plays a key role in glucose metabolism and influences antipsychotic-induced weight gain (AIWG). Our study is the first to investigate the encoding gene, GCG, and the GLP-1 receptor gene, GLP1R, and association with AIWG. MATERIALS & METHODS:In 216 schizophrenic patients treated with antipsychotics for up to ...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.13.247

    authors: Brandl EJ,Tiwari AK,Chowdhury NI,Zai CC,Lieberman JA,Meltzer HY,Kennedy JL,Müller DJ

    更新日期:2014-03-01 00:00:00

  • Pharmacogenomic biomarkers for personalized medicine.

    abstract::Pharmacogenomics examines how the benefits and adverse effects of a drug vary among patients in a target population by analyzing genomic profiles of individual patients. Personalized medicine prescribes specific therapeutics that best suit an individual patient. Much current research focuses on developing genomic biom...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.13.75

    authors: Chen JJ,Lin WJ,Chen HC

    更新日期:2013-06-01 00:00:00

  • Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population.

    abstract:AIMS:To determine whether there is an association between CFH, ARMS2, HTRA1, VEGF, SERPING1 or C3 genotypes and patient response to treatment with intravitreal bevacizumab for neovascular age-related macular degeneration (AMD). MATERIALS & METHODS:This was a multicenter prospective study. One hundred and forty four pa...

    journal_title:Pharmacogenomics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.2217/pgs.12.53

    authors: Tian J,Qin X,Fang K,Chen Q,Hou J,Li J,Yu W,Chen D,Hu Y,Li X

    更新日期:2012-05-01 00:00:00

  • The application of CD antigen proteomics to pharmacogenomics.

    abstract::The advent of multiplexing technologies has raised the possibility that disease states can be defined using discrete genomic and proteomic patterns or signatures. However, this emerging area has been limited by the 'content problem', arising from the uncertainty of which molecules to focus on. The human cluster of dif...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.7.5.759

    authors: Woolfson A,Ellmark P,Chrisp JS,A Scott M,Christopherson RI

    更新日期:2006-07-01 00:00:00

  • Pharmacogenetics of aspirin-intolerant asthma.

    abstract::Leukotriene overproduction is the major characteristic of aspirin-intolerant asthma (AIA). Most studies examining the molecular genetic mechanisms of AIA have focused on leukotriene-related genes, including ALOX5, LTC4S, TXA2R and prostanoid-receptor genes. One study suggested that the human leukocyte antigen (HLA) al...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.9.1.85

    authors: Kim SH,Hur GY,Choi JH,Park HS

    更新日期:2008-01-01 00:00:00

  • Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways.

    abstract::Cancer patients frequently suffer from disease- and treatment-related pain, nausea and depression, which severely reduces patients' quality of life. It is critical that clinicians are aware of drug-gene interactions and recognize the utility of applying pharmacogenetic information to personalize and improve supportive...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.15.178

    authors: Andersen RL,Johnson DJ,Patel JN

    更新日期:2016-03-01 00:00:00

  • Genetics of chronic obstructive pulmonary disease: a succinct review, future avenues and prospective clinical applications.

    abstract::Chronic obstructive pulmonary disease (COPD) is influenced by genetic and environmental factors. A large number of candidate gene-association studies and genome-wide linkage scans have been conducted to elucidate the genetic architecture underlying this disease. The compilation of these studies clearly revealed the co...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.09.10

    authors: Bossé Y

    更新日期:2009-04-01 00:00:00

  • Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes.

    abstract:AIMS:To study the frequency distribution of cytochrome P450 (CYP) functional genetic variants in five Eurasian populations from the territory of Siberia in Russia. MATERIALS & METHODS:Unrelated healthy Tuvinians, Buryats, Altaians, Yakuts and Russians (n = 87-88) were genotyped for CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/14622416.9.7.847

    authors: Makeeva O,Stepanov V,Puzyrev V,Goldstein DB,Grossman I

    更新日期:2008-07-01 00:00:00

  • The pharmacogenetics of NAT: structural aspects.

    abstract::Arylamine N-acetyltransferases (NATs) catalyze the transfer of an acetyl group from acetyl-CoA to arylhydrazines and to arylamine drugs and carcinogens or to their N-hydroxylated metabolites. NAT plays an important role in detoxification and metabolic activation of xenobiotics and was first identified as the enzyme re...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/14622416.3.1.19

    authors: Pompeo F,Brooke E,Kawamura A,Mushtaq A,Sim E

    更新日期:2002-01-01 00:00:00

  • Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective.

    abstract::Clozapine is the only effective antipsychotic for treatment-resistant schizophrenia but remains widely under prescribed, at least in part due to its potential to cause agranulocytosis and neutropenia. In this article, we provide an overview of the current understanding of the genetics of clozapine-associated agranuloc...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs-2018-0188

    authors: Legge SE,Walters JT

    更新日期:2019-03-01 00:00:00

  • Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.

    abstract:AIMS:Carvedilol is an effective treatment in hypertension and chronic heart failure. The medical impact of polymorphisms in CYP2D6 and in the β-adrenergic receptors ADRB1 and ADRB2 on the pharmacokinetics and pharmacodynamics of carvedilol is controversial. METHODS:After carvedilol 25 mg was administered to 110 volunt...

    journal_title:Pharmacogenomics

    pub_type: 临床试验,杂志文章

    doi:10.2217/pgs.11.20

    authors: Sehrt D,Meineke I,Tzvetkov M,Gültepe S,Brockmöller J

    更新日期:2011-06-01 00:00:00

  • Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.

    abstract::While antidepressants are widely used to treat mood and anxiety disorders, only half of the patients will respond to antidepressant treatment and only one-third of patients experience a full remission of symptoms. The identification of genetic biomarkers that predict antidepressant-treatment response can improve curre...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/pgs.12.1

    authors: Narasimhan S,Lohoff FW

    更新日期:2012-03-01 00:00:00

  • Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy.

    abstract::Interferon-β (IFN-β) and glatiramer acetate are routinely used to inhibit disease activity in multiple sclerosis, but their mechanisms of action are incompletely understood. Individual treatment responses vary and candidate molecular markers that predict them have yet to be established. Why some patients respond poorl...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章

    doi:10.2217/pgs.10.190

    authors: Goertsches RH,Zettl UK,Hecker M

    更新日期:2011-03-01 00:00:00

  • Adducin polymorphisms and the treatment of hypertension.

    abstract::Hypertension is an important public health problem affecting more than 50 million individuals in the USA alone. The most common form, essential hypertension, results from the complex interplay between genetic predisposition and environmental influences. Epidemiological, migration, intervention and genetic studies in h...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.5.465

    authors: Manunta P,Citterio L,Lanzani C,Ferrandi M

    更新日期:2007-05-01 00:00:00

  • Mapping translational research in personalized therapeutics: from molecular markers to health policy.

    abstract::Translational research is frequently used in the bioscience literature to refer to the translation of basic science into practical applications at the point of patient care. With the introduction of theragnostics, a new medical subspecialty that fuses therapeutics and diagnostic medicine with the goal of providing ind...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.2217/14622416.8.2.177

    authors: Ozdemir V,Williams-Jones B,Cooper DM,Someya T,Godard B

    更新日期:2007-02-01 00:00:00

  • Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology.

    abstract::The number of reports investigating disease susceptibility based on the carriage of low-penetrance, high-frequency polymorphisms has steadily increased over the last years. Evidence based on meta-analyses of individual case-control studies is accumulating, defining specific individual variations in disease susceptibil...

    journal_title:Pharmacogenomics

    pub_type: 杂志文章,评审

    doi:10.1517/phgs.5.1.57.25687

    authors: Tempfer CB,Schneeberger C,Huber JC

    更新日期:2004-01-01 00:00:00